Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, discusses a randomized trial assessing health-related quality of life in patients with 

-positive non—small cell lung cancer who were treated with brigatinib (Alunbrig) versus crizotinib (Xalkori).

The study, updated quality-of-life data of which were presented at the 2019 World Conferenc on Lung Cancer, demonstrated that brigatinib is favorable in these patients, including those with brain metastases. Overall, brigatinib was superior in improving health-related quality of life.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

IASLC World Conference on Lung Cancer

Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, talks about a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer patients who were treated with brigatinib versus crizotinib.

Dr. Campelo on the Rationale for the ALTA-1L Trial